Ameriprise
BBNX

Ameriprise’s Beta Bionics BBNX Stock Holding History

Ameriprise’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,409
Closed -$988K – 4249
2025
Q4 		$988K Sell
32,409
-3,081
-9% -$82.3K ﹤0.01% 3346
2025
Q3 		$705K Buy
35,490
+14,719
+71% +$259K ﹤0.01% 3502
2025
Q2 		$302K Sell
20,771
-33,254
-62% -$471K ﹤0.01% 3694
2025
Q1 		$661K Buy
+54,025
New +$1.01M ﹤0.01% 3386

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameriprise's BBNX Position: Q1 2026 in Review

Ameriprise sold out of Beta Bionics (BBNX) in Q1 2026, closing a stake of 32,409 shares — an estimated $988K sold.

Ameriprise first reported a position in BBNX in Q1 2025 and held it in 4 quarters. The position peaked at $988K in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Ameriprise reported no remaining Beta Bionics position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 32,409 Beta Bionics shares in Q1 2026, an estimated $988K.
  • Ameriprise first reported a position in Beta Bionics in Q1 2025 and held it in 4 quarters.
  • Ameriprise's Beta Bionics position peaked at $988K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.